Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer

This phase I trial tests the safety, side effects, and best dose of TAG72-chimeric antigen receptor (CAR) T cells in treating patients with epithelial ovarian cancer that remains despite treatment with platinum therapy (platinum resistant). T cells are infection fighting blood cells that can kill tumor cells. The T cells given in this study will come from the patient and will have a new gene put in them that makes them able to recognize TAG72, a protein on the surface of tumor cells. These TAG72-specific T cells may help the body's immune system identify and kill TAG72+ cancer cells.

Trial Details

NCT ID

NCT05225363

Phase

PHASE1

Sponsor

City of Hope Medical Center

Status

RECRUITING

Cancer Type

Ovarian Cancer

Interventions

Chimeric Antigen Receptor T-cells
Cyclophosphamide
Fludarabine

Locations (sample)

Duarte, California, United States|34.13945,-117.97729

Key Eligibility Criteria

Participant must have the ability to understand and the willingness to sign a written informed consent.
Agreement to allow the use of archival tissue from diagnostic tumor biopsies. If unavailable exceptions may be granted with Study PI approval.
Age \> 18 years.
ECOG Performance status 0 - 2 or KPS ≥70%.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →